Last reviewed · How we verify
Etanercept + Acitretin
Etanercept blocks TNF-α signaling while acitretin normalizes keratinocyte differentiation and reduces inflammation, together targeting both immune and skin-barrier dysfunction in psoriasis.
Etanercept blocks TNF-α signaling while acitretin normalizes keratinocyte differentiation and reduces inflammation, together targeting both immune and skin-barrier dysfunction in psoriasis. Used for Moderate-to-severe plaque psoriasis, Psoriatic arthritis.
At a glance
| Generic name | Etanercept + Acitretin |
|---|---|
| Also known as | Etancercept 25mg and Acitretin 10mg |
| Sponsor | Pfizer |
| Drug class | TNF inhibitor + retinoid combination |
| Target | TNF-α receptor (p75/p55) + retinoid X receptor (RXR) and retinoic acid receptor (RAR) |
| Modality | Small molecule |
| Therapeutic area | Dermatology / Immunology |
| Phase | FDA-approved |
Mechanism of action
Etanercept is a TNF receptor fusion protein that neutralizes tumor necrosis factor-alpha, a key driver of systemic inflammation in psoriasis. Acitretin is a retinoid that modulates gene expression in skin cells, promoting normal differentiation and reducing hyperproliferation. The combination addresses both the underlying immune dysregulation and the abnormal skin cell behavior characteristic of moderate-to-severe psoriasis.
Approved indications
- Moderate-to-severe plaque psoriasis
- Psoriatic arthritis
Common side effects
- Injection site reactions
- Headache
- Infections (upper respiratory, sinusitis)
- Lipid abnormalities (from acitretin)
- Hepatotoxicity
- Teratogenicity (acitretin)
- Dry skin and mucous membranes
Key clinical trials
- Swiss Dermatology Network of Targeted Therapies (SDNTT)
- Treatment Effectiveness Among Psoriasis Patients Treated With Cosentyx (Secukinumab)
- Spanish Registry of Systemic Treatments in Psoriasis
- Comparative Effectiveness of Psoriasis Treatments on Systemic Inflammation
- Economic Evaluation of Systemic Treatments for Moderate-to-severe Psoriasis
- Trial of an Injectable Biologic and U0279 as Combination Therapy for Severe Plaque-Type Psoriasis (PHASE4)
- Acitretin and Etanercept in Psoriasis (PHASE2)
- Regulatory T-cells in Psoriasis Patients as Targets for Therapy
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Etanercept + Acitretin CI brief — competitive landscape report
- Etanercept + Acitretin updates RSS · CI watch RSS
- Pfizer portfolio CI